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Available online 4 May 2017Reactivation of latent viral reservoirs is on the forefront of HIV-1 eradication research. However, it is unknown if
latency reversing agents (LRAs) increase the level of viral transcription from cells producing HIV RNA or
harboring transcriptionally-inactive (latent) infection. We therefore developed a microfluidic single-cell-in-
droplet (scd)PCR assay to directly measure the number of CD4+ T cells that produce unspliced (us)RNA and
multiply spliced (ms)RNA following ex vivo latency reversal with either an histone deacetylase inhibitor
(romidepsin) or T cell receptor (TCR) stimulation. Detection of HIV-1 transcriptional activity can also be per-
formed on hundreds of thousands of CD4+ T-cells in a single experiment. The scdPCRmethod was then applied
to CD4+ T cells obtained from HIV-1-infected individuals on antiretroviral therapy. Overall, our results suggest
that effects of LRAs on HIV-1 reactivation may be heterogeneous—increasing transcription from active cells in
some cases and increasing the number of transcriptionally active cells in others. Genomic DNA and human
mRNA isolated from HIV-1 reactivated cells could also be detected and quantified from individual cells. As a
result, our assay has the potential to provide needed insight into various reservoir eradication strategies.ering D
mothy.
. This i© 2017 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Histone deacetylase inhibitors1. Introduction
Despite the success of combination antiretroviral therapy (ART) to
reduce disease-related morbidity and mortality in HIV-1 infection,
viral reservoirs still persist in the setting of intensive therapy. The
main challenge in achieving a cure for HIV-1 is the elimination of
these latent viral reservoirs (Chun et al., 1997; Deeks et al., 2016; Finzi
et al., 1997; Richman et al., 2009; Siliciano, 2010; Wong et al., 1997).
Many HIV-1 eradication strategies are based on the “shock and kill”epartment by courtesy.
henrich@ucsf.edu
s an open access article underapproach,which involves reactivating infected cellswith latency revers-
ing agents (LRAs; e.g.,vorinostat, romidepsin, panobinostat), triggering
viral production. Ideally, HIV-1 producing cells are then cleared by im-
mune mediated and direct cytopathic mechanisms, while uninfected
cells are protected by ART (Archin et al., 2014; Barton et al., 2016;
Bullen et al., 2014; Elliott et al., 2014; Laird et al., 2015; Leth et al.,
2016; Rasmussen et al., 2013, 2014). However, viral reactivation alone
is insufficient to reduce HIV-1 DNA reservoirs (Rasmussen et al.,
2014), and associations between HIV-1 transcriptional activity and the
number or percentage of reactivated individual cells are poorly under-
stood (Chun et al., 1997; Eriksson et al., 2013; Ho et al., 2013;
Josefsson et al., 2011; Laird et al., 2013; Procopio et al., 2015; Siliciano
and Siliciano, 2005; Varadarajan et al., 2012). Even when latency
is effectively reversed, it remains unknown if the enhanced HIVthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
218 R.W. Yucha et al. / EBioMedicine 20 (2017) 217–229transcription comes from an already active pool, or from latently infect-
ed cells that reactivate and newly express HIV-1 RNA.
Cellular HIV-1 burden can be characterized by PCR quantification of
cell-associated genomic and episomal DNA or cell-associated total,
unspliced (us)RNA and multiply spliced (ms)RNA (Eriksson et al.,
2013; Kiselinova et al., 2014; Pasternak et al., 2008; Procopio et al.,
2015; Strain and Richman, 2013). However, assays involving these
methods have traditionally focused on quantifying nucleic acid levels
from bulk mononuclear cell lysates rather than from individual cells.
As a result, these assays may attribute viral production to the entire
pool of infected cells, whereas only a portion of latently infected cells
may be able to reactivate and produce replication competent virus
(Ho et al., 2013). Techniques to quantify inducible HIV-1 burden with
single-cell resolution have recently been developed, including an
assay that couples intracellular HIV RNA by probe hybridization with
HIV p24 detection in flow cytometric methods (Baxter et al., 2016).
However, these assays typically use or require a high degree of ex vivo
stimulation in order to detect and quantify transcriptionally or
translationally active cells. Other droplet-based single cell systems are
either cost prohibitive, currently lack built in technology to combine
viral target specific detection in addition to human polyadenylated
mRNA, or lack sufficient throughput to survey the millions of cells
required to indentify and characterize HIV in the setting of ART
(Macosko et al., 2015; Shalek et al., 2014; Trivedi et al., 2015; Zheng et
al., 2017). As a result, there is an urgent need for studies that examine
the number or percentage of individual reactivated primary human
cells that may be susceptible to targeted immune or pharmacologic kill-
ing (Josefsson et al., 2011; Strain and Richman, 2013), and how these
numbers correlate with the total amount of cell-associated RNA being
produced by an infected cell pool. Such studies may provide insight re-
gardingwhether LRAs increase the level of viral transcription from cells
already activated, or from inactive, latently infected cells that reactivate
and newly express HIV-1 RNA.
Here, we describe a methodology that allows for isolation and
enumeration of individual latently infected lymphocytes and other
tissue-derived cells. Individual CD4+ lymphocytes, macrophages, and
brain-derived glial cells were encapsulated into nanoliter-scale reaction
droplets via bioprinting and/or microfluidic approaches. Once encapsu-
lated, downstream applications such as intra-droplet lysis and PCR
amplification of HIV-1 usRNA and msRNA target sequences were
performed. We have successfully applied this method to identify and
quantify transcriptionally active individual CD4+ T cells from peripheral
blood of HIV-1-infected individuals on ART to determine the ex vivo
responses to various reactivating agents. We also have performed
proof-of-concept studies demonstrating that genomic DNA and human
mRNA can be isolated and quantified from individual encapsulated
and lysed human cells. Our results suggest that the number of single
cells that undergo HIV-1 reactivation is independent of total cell-associ-
ated HIV-1 RNA levels measured by traditional assays, and that the pro-
duction of usRNA and msRNA in response to LRA may vary between
clinical samples as well as within cells from a single individual. Our
results highlight the importance of direct single-cell analysis to
fully understand the impact of reactivating agents on latently HIV-
infected cells.
2. Materials and Methods
2.1. Materials and Reagents
Cell culture reagents include RPMI-1640 + L-glutamine, penicillin/
streptomycin 100×, Hepes buffer, fetal bovine serum heat inactivated,
and 1× phosphate buffered saline (Corning Cellgro, Manassas, VA).
Cell staining formicroscopy andflow cytometry consist ofMitoTracker®
Orange (Life Technologies, Carlsbad, CA), LIVE/DEAD®Fixable BlueDead
Cell Stain Kit (Life Technologies), Anti-HLA-DR APC-Cy7 (BD Biosci-
ences, San Jose, CA), and CD38 PE-Cy7 (BD Biosciences). Cellencapsulation and lysis were performed using commercially available
droplet generation oil (BioRad, Hercules, CA) and lysis buffer containing
up to 10% final concentrations of decaethylene glycol mono-dodecyl
ether (Sigma, St. Louis, MA), Tris-HCl, Ph8 (Fisher Scientific, Pittsburgh,
PA). scdPCR mastermix included the OneStep RT ddPCR Kit (BioRad).
Bulk genomic extraction for qPCR was completed with an AllPrep
DNA/RNA Mini Kit (Qiagen, Hilden, Germany). PCRs were performed
on either ABI 7300 Real Time PCR Machine (Applied Biosystems),
Roche LightCycler® 480 II (Roche Diagnostics, Basel, Switzerland), or
QX100 Droplet Reader (BioRad), and thermocycled using a GeneAmp®
PCR System 9700 (Applied Biosystems). Laboratory cell lines included
the HIV-infected 8E5/LAV lymphocyte, ACH2 and U1 cell lines (NIH
AIDS Reagent Program); adherent macrophages were derived from
mononuclear cells (humanmyeloid U937 cells) using phorbol myristate
acetate (Hattori et al., 1983).
2.2. Human Subjects, Sample Collection, Cell Isolation, Culture, and
Reactivation
Approval was obtained by the Brigham andWomen's Hospital/Part-
ners Healthcare Review Board and the University of California Review
Committee on Human Research for the collection and testing of cells
from HIV-1-infected individuals. Participants provided written in-
formed consent prior to enrollment. Peripheral blood mononuclear
cells (PBMC) were obtained from peripheral blood by density-gradient
centrifugation using the Ficoll-Paque (Sigma). CD4+ T-cells were iso-
lated from frozen peripheral blood mononuclear cells (PBMCs) using
the EasySep™ Human CD4+ T-cell Enrichment Kit (Stem Cell Technol-
ogies) under manufacturer's instructions. Purified CD4+ T-cells were
then cultured in RPMI-1640 with 10% FBS, 1% penicillin/streptomycin,
1% HEPES buffer, and supplemented with 1 ng/mL interleukin-2
(R-10). To prevent any potential HIV-1 infection in culture all samples,
including HIV-1 negative controls, were treated with 8 nM efavirenz
and 10 nM darunavir (ART).
CD4+ T-cell reactivation was performed through either T-cell re-
ceptor (TCR) activation or histone deacetylase inhibitor (HDACi) treat-
ment. For a majority of experiments, TCR mediated reactivation was
achieved through overnight culture in the presence of 100 ng/mL anti-
CD-3 and anti-CD-28 antibodies (Miltenyi Biotech). HDACi treatment
included a 4 h pulse with 5 nM romidepsin followed by washing, resus-
pension in new medium and culture in R-10 + ART for an additional
14 h. Nonstimulated controls were cultured in R-10 + ART. Laborato-
ry-infected U1 promonocyte cells were reactivated with anti-CD-3 and
anti-CD-28 antibodies as above orwith 10μg/ml of PHA for approximate-
ly 18 h. Experiments involving CD4+ T cells were also performed using
both 18 h and 3 day activation culture times prior to encapsulation.
2.3. Cell Encapsulation and SCDPCR
Cell encapsulation was performed using an in-house set-up
consisting of a syringe pump, commercially available microfluidic chips
(Biorad), droplet generation oil, cell lysis buffer, and PCR mastermix (all
Biorad). Cells were washed and resuspended in PBS at 5 × 105 or
1 × 106 cells/mL, and mixed 1:1 with PCR mastermix (Supplementary
Table 1). To minimize extradroplet lysis and RNA contamination, 5%
final concentration of lysis buffer was added immediately prior to encap-
sulation. Droplet generation and cell encapsulationwas performed under
negative pressure flow conditions using a reverse syringe pump attached
to the outflow well of a BioRad ddPCR encapsulation chip with flexible
tubing. Droplet generator oil (70 μL) was placed in the oil inlet well of
the chip, followed by 20 μL of cell/mastermix suspension in the middle,
sample loading well. Immediately prior to negative pressure encapsula-
tion, lysis buffer was added and mixed gently in the sample well. The
droplet/oil suspension was then transferred from the output well to
a PCR plate well using caution as to not shear droplets. SCDPCR
thermocycling conditions are listed in Supplementary Table 1. Finally,
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ital PCR system for quantification. Quantification is performed by first
setting a threshold above negative control samples, followed by normal-
ization to the estimated number of encapsulated cells, and then a final
background subtraction for any low-level false positives. For cell encap-
sulation efficiency studies cells were first stained with MitoTracker® Or-
ange under manufacturer's instructions, and 2× Control Buffer was used
in place ofmastermix. Encapsulation efficiencywas calculated by analyz-
ing multiple fluorescent images using ImageJ software (NIH, Bethesda,
MD).
2.4. Bulk PCR and Flow Cytometry
Flow cytometry was used to determine the effects of culture condi-
tions on cell viability and cellular activation. Briefly, cells were washed
and resuspended in PBS at 1 × 106 cell/mL, stained with LIVE/DEAD®
Fixable Blue Dead Stain Kit at room temperature for 30 min, washed
and resuspended in 100 μL PBS, stained with HLA-DR APC-Cy7 and for
20 min at room temperature in the dark, and fixed with 200 μL of 4%
paraformadehyde for 30 min. Flow cytometry was performed on a BD
™ LSRII flow cytometer using FACSDiva™ software (BD).
Bulk quantitative PCR methods were utilized to determine amounts
of cell-associated HIV-1 unspliced and multiply-spliced RNA. RNA and
DNA were extracted from cells using the AllPrep DNA/RNA Mini Kit
(Qiagen). Unspliced RNA was quantified using reverse transcriptase,
quantitative PCR as previously described (Malnati et al., 2008). Multi-
ply-spliced RNA was quantified using droplet digital PCR as
described(Kiselinova et al., 2014). Quantified RNA values were then
normalized to total cell counts determined through qPCR for CCR5
DNA, expressed as number of copies per 1 × 106 cells as previously
described (Malnati et al., 2008).
2.5. Droplet Sorting, Isolation and gDNA/mRNA Quantification
Patient-derived CD4+T cells ormixtures of 8E5 andHIV-uninfected
PBMCwere encapsulated. Following scdPCR, dropletswere layered onto
a thin film of droplet generator oil under an inverted fluorescentmicro-
scope on the underside of a 6-well culture plate cover. Individual drop-
lets containing HIV-1 usRNA producing cells were then selected based
on positive fluorescence using an ultrafine (32 gauge) flexible, stainless
steel needle (Hamilton) attached to a 2 ml lure-lock syringe. For RNA
isolation, single dropletswere placed in 10 μL of single-cell lysis solution
with DNase I (Ambion/ThermoFisher) followed by incubation at room
temperature for up to 10 min as per manufacture protocols. For DNA
isolation, single droplets were placed in 7.5 μL of PicoPure (Applied
Biosystems) DNA extraction solution followed by heat incubation in a
thermocycler as per the manufacturer protocols. Human CCR5 DNA
was quantified using real-time PCR as previously described (Malnati
et al., 2008). Human IPO8 transcripts were quantified using the
PrimePCR (Bio-Rad) ddPCR Gene Expression Probe assay using manu-
facturer protocols following reverse transcription of the RNA droplet/
cell lysis extracts suing the RETROscript® Reverse Transcription Kit
(Ambion; ThermoFisher Scientific). Fluorescent droplets containing
HIV-1 us RNA without cellular material were used as negative controls
to very that there was no fluorescent signal carried over into IPO8
ddPCR experiments.
2.6. Data and Statistical Analysis
Fluorescent micrographs were analyzed using ImageJ Software. PCR
datawas analyzed using either theABI 7300 SDS Shell, LightCycler®480
Software 1.5.1, or QuantaSoft 1.3 software. Regression, correlation,
Student's t-test, and/or ANOVA (alpha level = 0.05) were performed
using GraphPad Prism 6 (GraphPad Software, Inc., La Jolla, CA) and
SPSS vs 21 (IBM).2.7. Droplet Bioprinting
Droplets were printed using pressurized nitrogen gas nozzle
(TechElan, Mountainside, NJ) driven by a pulse/function generator
(Hewlett-Packard, Palo Alto, CA) with the following optimized settings:
Square pulse waveform with a 25–200 Hz frequency, 60 μs width, 2 V
amplitude with no offset, 2m30s time, and 2 PSI pressure.
3. Results
3.1. System Overview: Single-Cell-in-Droplet (scd)PCR
Single-Cell-in-Droplet (scd)PCR is a technique developed to enable
intra-droplet cell lysis and PCR amplification of intracellular RNA with-
out interfering with histone/chromatin bound DNA or PCR enzymes as
shown in Fig. 1. scdPCR can be used to quantify HIV-1 latent reservoir
reactivation frequencies by encapsulating and lysing single cells within
the isolated microenvironment of a droplet, with subsequent intra-
droplet PCR amplification of target HIV-1 usRNA andmsRNA. Following
PCR amplification of a specific target of interest, such as HIV-1 cell-asso-
ciated RNA, enumeration of fluorescing droplets is performed. Droplets
can then be isolated based on fluorescence followed by downstream
quantification of genomic DNA and human mRNA from bulk or single
cells.
3.2. Single-cell Encapsulation
We packaged primary human CD4+ T lymphocytes, macrophages
derived from the U937 mononuclear cell line and brain derived U118-
MG gliobastoma cells into droplet digital PCR (ddPCR)mastermix drop-
lets using both bioprinting and microfluidic technologies as shown in
Fig. 1. Bioprinting techniques were based on our previously published
nanoscale droplet methods to isolate and pattern single cells from het-
erogeneous cell suspensions (Ceyhan et al., 2012; Moon et al., 2011).
In brief, cell/mastermix suspensions are simultaneously forced through
a micro-nozzle by pressurized inert gas. An input concentration of 10-
5 cells/mL yielded the most efficient single-cell encapsulation, with
32% of bioprinted droplets containing a single cell and 5.7% containing
2 cells, as determined by lightmicoscopy.We identified similar packag-
ing efficiencies with glioblastoma cells, adherent macrophages and
CD4+ T cells (Fig. 2). Bioprinting allows for relatively tight control
over droplet size, but involves the use of specialized equipment and
trained personnel. As a result, we incorporated a commercially available
microfluidic chip for single-cell encapsulation (ddPCR cartridge origi-
nally designed for the QX100/200 platform). These chips generate 0.9
to 1.1 nanoliter droplets that can be used with the QX100/200 droplet
reader (a flow cytometer involving oil rather than sheath fluid in
order to preserve droplet integrity during enumeration) and were
used for the remainder of experiments described below.Weencapsulat-
ed single-cells by applying negative pressure to the output well of
microfluidic chips, combining mastermix with surfactant laden sili-
con-based oil. This method negated the need for the costly commercial
equipment required for efficient, high-throughput encapsulation. The
compositions of droplet lysis and PCR mastermixes are shown in
Supplemental Table 1.
To determine optimal encapsulation parameters, uninfected labora-
tory A3.01 lymphocyte cell lines and CD4+ T cells isolated from HIV-
uninfected donors were stained with MitoTracker Orange, and
packaged at various cell densities using the QX100 microfluidic chips
(Fig. 2). A concentration of 1 × 106 cells/mL yielded encapsulation
with approximately 22% of droplets containing a single cell, fewer
than 5% of droplets containing 2 or more cells, and b1% of cells contain-
ing more than three cells (Fig. 2). This patterns approximates the theo-
retical Poisson distribution in cell encapsulation as we have previously
described (Moon et al., 2011). Cells within droplets were easily visible
via standard fluorescent microscopy; approximately 50% of input cells
Fig. 1. Schema of the single cell encapsulation, lysis, HIV-1 detection, and rescue of cellular genomic DNA and mRNA. Cells are encapsulated in a master mix including PCR enzymes,
primers, probes, and cell lysis agents (Supplementary Table 1) into oil by either brioprinting or microfluidic chip encapsulation (A, B) as described in the methods. Up to 20,000
droplets are then added to each well of a 96 well PCR plate. Cells are lysed within isolated droplet microenvironenments followed by PCR amplification of Tat-Rev spliced or unspliced
cell-associated HIV-1 RNA (C). Cells are contained in the hydrophilic droplets which are stabilized by the oil-droplet interface. Droplets containing infected cells can be enumerated
using an oil-based commercial flow cytometer or by direct visualization followed by microfluidic sorting of positive droplets (D). HIV-1 RNA positive or negative cells can be isolated
using ultrafine needle aspiration, placed into individual microwell tubes or plate wells followed by droplet “cracking” (i.e. lysing droplets to release nucleic acids) and further
characterized. In this study, human or viral genomic DNA and human mRNA from droplets containing a single encapsulated cell or from bulk droplets containing HIV-1 RNA positive
cells were quantified or sequenced.
220 R.W. Yucha et al. / EBioMedicine 20 (2017) 217–229are successfully encapsulated. Up to 20,000 droplets were created in
each well of the BioRad chips, which were then transferred to a single
well of a 96-well PCR plate, allowing for N500,000 cells to be surveyed
in a single PCR run; 160,000 droplets are able to be generated inFig. 2. Single cell packaging of various human cell lines. (A) Adherentmacrophages and (B) brai
microscopy following bioprinting. Arrows show individual cells encapsulated within fluid drop
cells. Few droplets contained 2 or more cells (b6%) and packaging efficiency was similar for m
MitroTracker orange encapsulated using microfluidic chips stained with MitoTracker in an o
staining allowed for the differentiation of encapsulated cells from air bubbles created durin
microscopy. (D) Packaging using microfluidic yielded 22% of droplets containing a single cel
cells/mL input concentration. Error bars represent standard error from 10 replicate experimenb5 min. As the number of RNA-expressing cells in a patient sample
are expected to be very low, this assay was designed to allow repetitive
sampling of hundreds of individual PCRwells for each sample or sample
condition.n-derived glioma cells packaged intomicrodoplets using bioprinting are shown under light
lets suspended in droplet generation oil. Approximately 32% of droplets containing single
acrophages, glioma cells and CD4+ T lymphoctes. (C) Human CD4+ T cells stained with
verlay of fluorescent signal (Red) on light microscopic images of droplets. MitoTracker
g microfluidic chip encapsulation which are of a similar size and appearance with light
l, and fewer than 5% of droplets containing 2 or more cells at a concentration of 1 × 106
ts.
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We developed the assay to detect cell-associated HIV-1 RNA while
leaving genomic viral DNA intact for downstream characterization and
to minimize confounding signal from cell-associated HIV-1 DNA. Fol-
lowing droplet generation, an initial heat step was incorporated to
allow reverse-transcription of target RNA and to aid in cell lysis, follow-
ed by exposure to higher temperatures (95 °C) to aid in cell lysis prior to
repetition of ddPCR cycles as outlined in the methods section. A final
high heat step (98 °C for 10 min) was incorporated to promote droplet
hardening. Hardened droplets are relatively resilient to sheer stress, and
we have demonstrated stability for up to 7 days at 4 °C without signifi-
cant loss of mechanical integrity. Initially, mixtures of various concen-
trations of HIV-1-infected 8E5/LAV and uninfected A3.01 lymphocyte
cell lines were encapsulated followed by lysis and thermocycling forFig. 3. scdPCR detection and quantification of HIV-1-infected 8E5/LAV cells. Fluorescentmicrosc
intradroplet lysis and target quantification for HIV-1 usRNA. Droplets containing 8E5/LAV cell
droplets without cells or those that contain uninfected lymphocytes. Positive fluorescent dro
mixture of 10% 8E5 and 90% uninfected lymphocytes is shown (C). Infected cells have flu
lymphocytes. Linear regression of the number of input 8E5/LAV cells to the mean number o
using scdPCR. Linearity was preserved down to 1 infected cell per 10,000 total input cells in
each sample, the assay has the sensitivity to detect as low as 10 cells per 106 total input cells
95% confidence intervals from curve-fit regression.PCR amplification of cell-associated HIV-1 usRNA and msRNA as de-
scribed in Supplementary Table 1. The 8E5/LAV line contains a single
copy of integrated HIV-1 LAV DNA with a mutation rendering replica-
tion incompetent virus. However, the cells are able to efficiently pro-
duce HIV RNA (Wilburn et al., 2016). Nearly all 8E5 cells produce
some level of cell-associated HIV-1 RNA during routine culture without
the presence of ART. Successful amplification resulted in visibly fluores-
cent droplets (Fig. 3A) containing 8E5/LAV cells but no increased signal
in droplets containing uninfected CD4+ T cells (Fig. 3B). Droplets can
also be enumerated using the QX100 reader as shown in Fig. 3C; the re-
sults demonstrate that positive and negative fluorescent droplets can be
readily enumerated using commercially available equipment. Gating
between positive and negative cells was performed using the QX100
software, with the cutoff line positioned above the values of the nega-
tive droplets. This gating strategy is analogous to a 2-dimensional gatingopic images of droplets containing 8E5/LAV cells (A) and uninfected CD4+ T cells (B) after
s demonstrate fluorescence from amplification of FAM probe that can be discerned from
plets can readily be quantified using the QX100 oil-based droplet reader; results from a
orescent amplitudes above baseline as determined by droplets containing uninfected
f infected cells containing HIV-1 usRNA (D) and msRNA (E) detected per reaction well
a single PCR well. Given the ability to perform repetitive sampling in multiple wells for
using a 96 well plate with known encapsulation efficiencies. Dotted lines represent the
222 R.W. Yucha et al. / EBioMedicine 20 (2017) 217–229strategy used in flow cytometry. Uninfected CD4+ T cell were encapsu-
lated and assayed in parallel experiments to aid with gating and to pro-
vide a measure of background noise; any droplet counts above the cut-
off value from negative control experiments were subtracted from the
experimental wells. Of note, PCR probe agglomerates within encapsu-
lated cells were observed, causing the bright spots on the images, and
were confirmed by dual stainingwith probe andMitoTracker. However,
these agglomerates did not cause interference with the ddPCR Droplet
Reader, and the reader software autocorrects for droplet size. Once
packaging efficiency was determined, experiments were performed
without the use of MitoTracker orange.
Mixtures of infected and uninfected laboratory cells. Ten to 200,000
HIV (LAV) infected 8E5/LAV cells were suspended along with 1 × 106
HIV-1-uninfected CD4+ T cells from donors in a final concentration of
1 × 106 cells/mL. Linear regression analyses comparing input and ex-
pected positive cell frequencies for each reaction well are shown in
Fig. 3D (usRNA) and Fig. 3E (msRNA). Quantification of usRNA and
msRNA producing droplets was then performed on approximately 50
to 100,000 positive cells spiked in uninfected lymphocytes across mul-
tiple wells. Over and entire experiment involving scdPCR was able to
consistently detect 10 cells expressing HIV-1 usRNA and msRNA per
1 × 106 total cells. This infected cell detection sensitivity was close and
within error to that predicted from data averaging performance within
individual wells (2 to 5 infected cell per 106 total input cells) as shown
in Fig. 3, taking into account minor variations in encapsulation
efficiencies.
3.4. Digital Droplet PCR Amplification of HIV-1 usRNA and msRNA
We performed experiments to determine if the usRNA or msRNA
primer/probes and single-cell conditions would also detect HIV-1
DNA, which could confound interpretation of cell-associated RNA target
amplification. The usRNA primer and probe sequences are the same as
those used for detection of cell-associated HIV-1 DNA (Malnati et al.,
2008). Unspliced RNA from encapsulated 8E5 cells was packaged into
droplets consisting of the same mastermix as described above. Follow-
ing thermocycling, fluorescent droplets were readily detected using
the QX100 droplet reader and fluorescent microscopy. Approximately
2xlog10 fewer positive droplets were observed when reverse-transcrip-
tasewas omitted, suggesting that the vastmajority of the positive signal
in our assay arises from RNA rather than genomic DNA. The msRNA
primers are designed for amplification of the Tat-Rev spliced sequence
spanning near full-length HIV-1 envelope, and are designed to have lit-
tle to no amplification of intact DNA sequences (Pasternak et al., 2008).
We did not detect DNA using the msRNA primers and probes despite
high levels of input HIV-1 DNA.
3.5. Safety of Thermocycled Droplets Containing HIV-1-infected Cells
In order to determine the safety of using thermocycled droplets for
downstream manipulations outside of a BL2+ containment setting,
we packaged dropletswith ACH2 cells containing replication competent
HIV-1 proviral DNA; these cells are capable of producing infectious
virus upon stimulation. We combined HIV uninfected A3.01 cells (neg-
ative control), with ACH2 cells, which were then subject to either
thermocycling alone or thermocycling after droplet encapsulation,
followed by incorporation into an infectivity assay using TZM-black
adherent cells or into a viral co-culture assay. High levels of β-galactosi-
dase, a surrogate for HIV-1 entry into TZM cells, were observed in
experiments incorporating unmanipulated ACH2 cells and the positive
control wells inoculated directly with infectious HIV-1 JRCSF
(RLU N 400,000; Supplementary Fig. 1). However, no signal was detected
in wells incorporating encapsulated or unencapsulated ACH2 cells fol-
lowing scdPCR thermocycling. Encapsulated, thermocycled ACH2 cells
did not lead to increasing HIV-1 RNA in supernatants over 14 days of
co-culture, with RNA levels being similar to DNA in supernatants derivedfromdead cells (Supplementary Fig. 1). As a result, themocycled droplets
were determined to have negligible infectious risk.
3.6. Single-cell Responses to HIV-1-reactivation andMitogen Stimulation of
Cell Lines Using scdPCR
In order to test the performance of scdPCR to detect increases in HIV
transcriptional activity following latency reversal or global cell activa-
tion, we incubated the HIV-1-infected U 937 (U1) promonocyte line
(Folks et al., 1987) following a 4 h pulse of the HDAC inhibitor,
romidepsin (RMD) and overnight culture in RMD-free growthmedium,
or for 18 h in thepresence of growthmediumaloneorwith themitogen,
phytohaemagglutinin (PHA). Cells were thenwashed, encapsulated and
sdcPCR performed using both HIV-1 usRNA and msRNA primers and
probes. U1 cells were used in lieu of 8E5-LAV cells as fewer U1 cells ex-
press detectable HIV-1 RNA without activation, and better represents
viral latency. Romidepsin exposure led to a large increase in bulk
HIV-1 usRNA, and both RMD and PHA increased the percentage of
cells expressing usRNA (Fig. 4A). Changes in HIV-1msRNA in the setting
of various stimuli were more variable, with decreased bulk RNA levels
and percentages of cells expressing msRNA observed following
romidepsin exposure (Fig. 4B).
3.7. Effects of T-cell Stimulation and HIV-1 Reactivation on Individual Viral
Transcriptionally Active Cells From Individuals on ART
Next, to determine the ex vivo single cell responses to T-cell receptor
stimulation and HDACi reactivation, CD4+ T-cells were isolated from
cryopreserved peripheral blood mononuclear cells (PBMC) obtained
from individuals on combination ART with various HIV-1 clinical set-
tings including those with undetectable viral load measurements or
low-level blips or viremic events (Table 1). These participants were in-
cluded in order to test the assay on a range of clinical scenarios thatmay
be expected in various interventional studies. Following overnight
resting in culture medium without exogenous cytokines or drugs,
isolated CD4+ T cells were activated through the T-cell receptor
(TCR) using αCD3/αCD28 antibodies or treated with pulse dosed
HDACi (romidepsin; RMD) in the setting of at least two antiretroviral
drugs in order to reverse HIV-1 latency, and induce viral transcription
and usRNA and msRNA production without de novo infection of HIV-1
uninfected cells. Cells were then split equally for: (i) encapsulation
and scdPCR at a concentration of 106 cells/mL, and (ii) bulk cell lysis
and usRNA and msRNA quantification using traditional real-time PCR
(usRNA) or ddPCR (msRNA) based on previously reported methods
(Kiselinova et al., 2014; Malnati et al., 2008; Pasternak et al., 2008).
The number of cells expressing HIV-1 usRNA and msRNA with and
without TCR simulation or HDACi use, as well as the absolute cell-asso-
ciated usRNA levels quantified by traditional quantitative PCR frombulk
extracts, are shown in Fig. 5. Overall, usRNA copies/106 CD4+ T cells
measured by traditional assay on bulk lysates increased after TCR stim-
ulation byαCD3/αCD28 antibodies in all participantswith undetectable
plasma HIV load measurements at the time of blood collection (Fig. 5;
participants A, B, C, and D). Three of these four individual (A, B, and D)
also experienced an increase in usRNA copies 24 h after romidepsin
pulse. Despite these expected increases in bulk usRNA levels, changes
in the number of cells producing usRNA as measured by scdPCR after
stimulation were variable, and at times, discordant with results from
traditional RNA measures. For example, despite a N1 log10 increase in
bulk RNA following HDAC inhibition for participant A, the number of
cells expressing usRNA decreased. Traditional qPCR results were more
variable in participants with low-level detectable viremia on ART at
the time of sample collection (E, F, G). Nonetheless, dichotomies
between qPCR and sdcPCR assay results were notable in each of these
samples. A high degree of reproducibility between independent exper-
iments was observed based on the size of error bars, and all scdPCR
values were greater than the assay limit of detection. A total of
Fig. 4. Single cell and bulk HIV-1 usRNA andmsRNA responses in HIV-1-infected U1 cells to various stimuli. (A) Bulk and single cell HIV-2 usRNAU1 responses tomitogen (PHA) or HDAC
inhibitor stimulation are shown in the left and right panels respectively. Romidepsin increased usRNA in bulk cell extracts as well as the percentage of cells expressing RNA. In contrast,
RMDdecreased bulkmsRNA production and the percentage of U1 cells expressingmsRNA (B). Error bars represent standard error for two parallel experiments (conventional qPCR) or up
to 16 individual experimental wells (scdPCR).
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msRNA assays for each activation condition. Given the high degree of
variation in HIV-RNA frequencies and levels between individuals,
there were no significant differences in responses to various stimuli
across all participants.
Traditional qPCR and scdPCR measures of msRNA in participants on
ART are shown in Fig. 6. With the exception of participant A, in whom
msRNA could not be detected in unstimulated or TCR stimulated
wells, msRNA copies/106 CD4+ T cells by traditional assay on bulk ly-
sates increased following TCR stimulation in all participant samples
tested (A though F). The responses to romidepsin pulse stimulation
were more variable, with increases noted in participants A, B, and D.
The numbers of cells expressing HIVmsRNAwere different from the re-
sponses seen by traditional assays. In some instances, increases in the
amount of bulk msRNA after stimulation or no stimulation increased
while the numbers of msRNA expressing cells decreased, and vice
versa. Given the high degree of variation in HIV-RNA frequencies and
levels between individuals, there were no significant differences in re-
sponses to various stimuli across all participants. However, each exper-
iment was reproducible when performed two to four times using
different cell aliquots on different experimental days.
In order to determine whether or not cell death during stimulation
and culture may have led to differences between ex vivo treatment
groups, viability decreased b6% for all samples following TCR stimula-
tion withαCD3/αCD28 antibodies, but RDP exposure decreased cell vi-
ability by up to 16.7% in participants A and D (Supplementary Table 2).
We also obtained flow data on the fold increase in the early activation
marker following stimulation in cells from participants B and C in
order to demonstrate that TCR stimulation led to global cell activationTable 1
Participant demographics, clinical status, CD4+ T cell counts, HIV-1 cell associated DNA, and v
Participant Age Years of ART at
time-point tested
Other clinical diagnosis
A 44 0.25 None
B 67 N10 None
C 54 4 None
D 56 See notea 4.7 years following allogeneic HSCT
E 27 See noteb 6.4 years following allogeneic HSCT
F 52 N5 N1 year post autologous HSCT for Hodgkin ly
G 46 2.6 7.4 months following completion of chemoth
for B cell lymphoma
H 37 9 None
I 61 21 None
ND = HIV RNA not detected.
a Restarted ART within a week of viral rebound following analytical treatment interruption;
b Restarted stable ART within 4 weeks of viral rebound following analytical treatment interr(i.e. positive activation control). Overall, exposure toαCD3/αCD28 anti-
bodies led to a 7.2 and 117-fold increases in the amount of CD69 expres-
sion in participants B and C, respectively, whereas RMD led to 0 and 1.8
fold increases.
We also performed scdPCR for HIV-1 usRNA andmsRNA in two indi-
viduals on suppressive ART with plasma viral load measurements b50
RNA copies/mL following reactivation for up to 3 days in order to deter-
mine single cell changes in transcriptional activity over time. As shown
in Fig. 7, we noted variability between the two patients with respect to
patterns of reactivation and between various time points (18 h and
3 days). Again, results were reproducible over two separate experi-
ments. The number of HIV-1 usRNA expressing CD4+ T cells from par-
ticipant H increased after both TCR and RMD stimulation after 18 h
whereas usRNA levels decreased with romidepsin exposure following
48 h in culture. TCR stimulation resulted in increased HIV-1 msRNA ex-
pressing cell numbers at both time points, with little change in the RMD
experiments compared with unstimulated controls.
3.8. Downstream HIV-1 DNA Rescue, Amplification, and Sequencing From
Thermocycled Droplets
We performed proof of concept experiments to demonstrate that
genomic HIV-1 DNA can be rescued from cells encapsulated and lysed
within droplets following scdPCR. First, in order to test if viral or
human genomic DNA degrades with repetitive thermocycling, 10 and
100 copies of both HIV-1 and human genomic DNA obtained from in-
fected 8E5/LAV cells were subjected to thermocycling mimicking the
conditions of scdPCR. Following thermocycling, real-time PCR was per-
formed on a secondaryHIV-1 and humanDNA target (HIV integrase andiral load at the time of sampling.
Last HIV load
(RNA copies/mL)
HIV DNA (DNA copies/106
CD4+ T cells)
CD4+ T cell counts
(cells/μl)
b50 3231 921
b50 898
b50 957
b50 5528 618
1530 16,157
mphoma 246 13,865 1063
erapy 85 422 221
b40 – 418
b40 – 371
participant had been on ART for approximately 18 months following re-initiation.
uption; participant had been on ART for approximately 15 months following re-initiation.
Fig. 5. Comparison of single cell HIV-1 usRNA results by scdPCR with traditional quantitative PCR measures of us RNA from participants on ART. usRNA copies/106 CD4+ T cells by
conventional assay on bulk lysates increased after 24 h of TCR stimulation by αCD3/αCD28 antibodies in all participants with undetectable plasma HIV load measurements at the time
of blood collection (A, B, C, D). Three of these four individual (A, B, and D) also experienced an increase in usRNA copies ~18 h after romidepsin pulse. Despite these expected increases
in bulk usRNA levels, changes in the number of cells producing usRNA as measured by scdPCR after stimulation were variable, and at times, discordant with results from traditional
RNA measures. For example, despite a N 1 log10 increase in bulk RNA following HDAC inhibition for participant A, the number of cells expressing usRNA decreased. Conventional qPCR
results were more variable in participants with low-level detectable viremia on ART at the time of sample collection (E, F, G). Assays were repeated two to four times with the
exception of participant G (limited sample), and error bars represent standard error of the mean between independent experiments. Reproducibility between independent
experiments was observed, and all scdPCR values were greater than the both the detection limit of the assay (1 log10 RNA expressing CD4+ T cells) and limit of linearity (2 log10 cells).
224 R.W. Yucha et al. / EBioMedicine 20 (2017) 217–229human CCR5, respectively, and as previously described (Cillo et al.,
2014; Malnati et al., 2008). Cycle threshold (Ct) values between prior
thermocycled and direct input DNAwere the same for each paired con-
dition (Supplementary Fig. 2), suggesting cellular DNA is not substan-
tially degraded during scdPCR, at least in the sequence areas targeted
by the real-time PCR primers and probes. Additionally, infected 8E5/
LAV mixed with uninfected A03.01 cells at ratios of 100% 8E5, 60:30
8E5:A03.01, and 100% A03.01, were encapsulated followed by scdPCR.
Thermocycled droplets fromeach reactionwellwerewashed of residual
oil phase, and DNA was extracted from all droplets within a well using
established phenol-chloroform lysis and silica gel-based column extrac-
tion protocols. HIV-1 integrase real-time PCRwas performed on the ex-
tracted DNA as described above. HIV-1 integrase gene was detected
exclusively in lysates from droplets containing 8E5/LAV cells at any
input concentration, but not fromDNAextracted fromdroplets contain-
ing only uninfected A03.01 cells. To demonstrate that we could amplify
and sequence portions of the HIV-1 genome following scdPCR in aggre-
gate droplets within a single scdPCR reaction well, we rescued HIV-1
DNA from droplets containing either 8E5/LAV or uninfected A3.01
cells.We successfully amplified hyper variable region of HIV-1 envelope
[C2-V4 (Sharkey et al., 2011)] (Supplementary Fig. 3) followed bypopulation sequencing of the target gene. Of note, scdPCR experiments
of both 8E5 laboratory cell lines and participant samples without re-
verse-transcriptase, and magnesium in place of manganese in the
mastermix yielded approximately 2 log10 fewer positive fluorescent
droplets, suggesting that a large majority of signal in our assay arises
from HIV RNA rather than HIV DNA.
3.9. Isolation and Quantification of Human Genomic DNA and mRNA From
Single HIV-1 Transcriptionally Active Patient-derived Cells
Finally, we performed proof-of-concept studies to demonstrate that
single droplets containing one HIV-1 infected and transcrtipionally ac-
tive cell determined by scdPCR can be isolated followed by rescue and
characterization of human genomic DNA or mRNA. Patient-derived
CD4+T cells (Participant F) or a 10%mixture of 8E5 andHIV-uninfected
PBMCwere encapsulated andHIV-1 usRNA scdPCR performed as above.
Following thermocycling, droplets were layered onto a thin film of
droplet generator oil under an invertedfluorescentmicroscope. Individ-
ual droplets containingHIV-1 usRNA producing cells were then selected
based on positive fluorescence using an ultrafine (32 gauge) flexible,
stainless steel needle attached to a 2 ml lure-lock syringe and placed
Fig. 6. Comparison of single cell HIV-1 tat-revmsRNA results by scdPCR with traditional quantitative PCRmeasures of CD4+ T cell-associatedmsRNA from participants on ART.With the
exception of participant A, inwhommsRNA could not be detected in unstimulated or TCR stimulatedwells, msRNA copies/106 CD4+ T cells by traditional assay on bulk lysates increased
following TCR stimulation in all participant samples tested (A though F). Aswith traditional usRNAmeasures on bulk cell lysates, the responses to romidepsin pulse stimulationweremore
variable, with increased noted in participants A, B, andD. The numbers of cells expressing HIVmsRNAwere different from the responses seen by traditional assays. In some cases, increases
in the amount of bulk msRNA after stimulation or no stimulation increased while the numbers of msRNA expressing cells decreased, and vice versa. Assays were repeated twice in
independent experiments, and error bars represent standard error between independent experiments. With the exception of a lack of detectable msRNA expressing cells in samples
from participant C, all scdPCR values were greater than both the detection limit of the assay (1 log10 RNA expressing CD4+ T cells) and limit of linearity (2 log10 cells), and results
were reproducible between independent experiments. (ND = no HIV RNA detected).
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RNA isolation, single dropletswere placed in 10 μL of single-cell lysis so-
lution with Dnase I (Ambion/ThermoFisher) followed by incubation at
room temperature for up to 10 min. For DNA isolation, single droplets
from the participant sample were placed in 7.5 μL of PicoPure (Applied
Biosystems) DNA extraction solution followed by heat incubation as per
the manufacturer protocols. Following lysis, we were able to detect a
conserved region of the human CCR5 gene from 3 out of 10 droplets iso-
lated based on HIV-1 usRNA positive produciton from participant F
using a qPCR method as described (Malnati et al., 2008). Ct values
from each positive reactions corresponded with the 1–5 copy number
range based on a standard curve (theqPCRhas linearity down to 10 cop-
ies/input well) which roughly correlated with the expected two copies
of the diploid gene (Fig. 8). No CCR5 was detected in negative template
control wells. We were also able to detect the human IPO8mRNA tran-
script in 3 out of 7 droplets tested from Participant F and 2 of 5 droplets
containing HIV-1 transcriptionally active 8E5 cells using the PrimePCR
(Bio-Rad) ddPCR Gene Expression Probe assay following reverse tran-
scription of the RNA droplet/cell lysis extracts (Fig. 8). The mean per-
cell IPO8 copy numbers were 2.6 and 21 for participant and 8E5 cells,
respectively.
4. Discussion
Assays that allow for the identification and characterization of single
HIV-1 infected cells are a top priority in the field of HIV persistence(Strain and Richman, 2013). Here, we report the design and implemen-
tation of a single-cell assay for the identification and quantification of
individual, transcriptionally active cells (i.e., those that produce HIV-1
usRNA or msRNA) and their responses to various ex vivo stimuli such
as antibody engagement of the T cell receptor and pulsed HDACi expo-
sure. We designed the assay to incorporate commercially available PCR
reagents, microfluidic droplet generating chips, and available equip-
ment to allow for the rapid implementation in a larger number research
groupswithout the need for customizedmicrofluidic devices. Using this
assay, we found that the scdPCR assay is able to reproducibly determine
the numbers of transcriptionally active cells from individuals on ART.
Furthermore, we found that human genomic DNA and mRNA can be
quantified from individual cells using the sdcPCR assay. Overall, our re-
sults suggest that effects of LRAs on HIV-1 reactivation may be
heterogeneous—increasing transcription from active cells in some
cases and increasing the number of transcriptionally active cells in
others.
scdPCR assay can provide ameasure of the numbers of HIV-1msRNA
and usRNA productive cells that can be directly correlated to traditional
measures of cell-associated RNA on bulk cell lysates. Of note, we ob-
served differences between msRNA and usRNA responses to TCR or
HDACi stimulation by both our scdPCR method and by traditional
qPCRmethods.Wewere also able to identify and quantify transcription-
ally active cells using scdPCR in all participant samples above the limit of
detection and within the linear range of the assay. Furthermore, scdPCR
has the sensitivity to reliably detect various HIV RNA transcripts even
Fig. 7. Longitudinal scdPCR results for CD4+ T cells from individuals on suppressive ART following reactivation for 18 h and 3 days. The numbers of HIV-1 usRNA and msRNA expressing
CD4+ T cells for participant H (A) and I (B) are shown. TCR stimulation or romidepsin exposure led to increased both unspliced and multiply spliced RNA positive cells following 18 h of
stimulation for both participants and after 48 h for participant I. However, 48 h stimulation led to variable responses in cells from participant H. Both individuals were on suppressive ART
with plasma RNA levels b50 copies/mL at the time of sampling. Assays were repeated twice, and error bars represent standard error of the mean between independent experiments.
226 R.W. Yucha et al. / EBioMedicine 20 (2017) 217–229without maximal exogenous stimulation. As a result, the assay has the
potential to explore more physiologic conditions that exist in partici-
pants undergoing HIV curative therapies.
Overall, we observed inter-individual variation in the single-cell re-
sponse to either global TCR stimulation or ex vivo reactivation of HIV-1
following HDACi exposure. For example, we observed an expectedFig. 8. Isolation of single scdPCR droplets based on HIV-1 usRNA fluorescence and subsequen
transcriptionally active 8E5 or participant-derived CD4+ T cell lysates obtained by scdPCR w
blunt needle (A). The percentages of individual droplet/cells with detectable CCR5 genomic DNincrease in usRNA after TCR and RMD stimulation from bulk extracts,
but observed amarked decrease in the number of single cells expressing
RNA after RMD exposure in participant A. RMD increased bulk msRNA
while both TCR stimulation and RMD exposure led to a decrease in the
number of HIV transcriptionally active cells in cells from the same indi-
vidual. It is possible that cell death fromdrug toxicity led to a decrease int human gDNA and mRNA characterization. Fluorescent droplets containing single HIV-1
ere isolated and placed in single-cell DNA or RNA lysis buffers using an ultrafine gauge
A using real-time PCR or IPO8 mRNA using traditional ddPCR are shown in (B).
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in live cells following stimulation for participants A and B. Furthermore,
we observed increases in the number of usRNA transcribing cells in
other individuals in the setting of RMD exposure, despite decreasing
total bulk usRNA. Despite these divergent findings, results were consis-
tent when repeated on different days using different cell aliquots. Fur-
thermore, we noticed differences between changes in HIV-1 usRNA
and msRNA levels from bulk extracts and the percentage of CD4+ T
cell expressing RNA in several other participants.
Several individuals did not have a marked rise in traditional mea-
sures of HIV RNA following TCR stimulation. In order to minimize
changes in packaging efficiencies, we opted to use free αCD3/αCD28
antibodies rather than the more potent antibody coated beads to per-
form these stimulations. Free antibodies take longer to stimulate T
cells and our activation protocol was restricted to 12–24 h prior to
encapsulation, which may have been insufficient to fully activate
the CD4+ T cell pools.
Prior studies have shown that increases inmsRNA coding for regula-
tory proteins, such as Tat/Rev. RNA as incorporated in our assay, are
seen earlier in the HIV life-cycle and precede increases in usRNA tran-
scripts, which are packaged into virions and are correlated with the
lytic phase of infection (Bagnarelli et al., 1996; Pasternak et al., 2013;
Pomerantz et al., 1990). It is therefore possible that decreases in the per-
centage of msRNA producing CD4+ T cells after RMD stimulation ob-
served in our study represent a shift away from early cycles of viral
reactivation towards the later, usRNA enriched stage. However, maximal
msRNA levels have been observed up to 12 h after stimulation in other
studies (Procopio et al., 2015) and our assaywas designed to incorporate
a similar simulation time.We also observed decreases in bulk usRNA and
the numbers of usRNA-expressing cells by traditional and scdPCR
methods. Interestingly, we observed stable or increased numbers of
msRNA positive cells following RMD exposure at both time-points in
our experiments involving 18 h and 3 day stimulations of cells from
two ART-suppressed individuals. As a result, shifts from msRNA to
usRNA may not completely explain the decreases in the percentage of
RNA producing cells observed in this study. Although it is possible that
the decreasing frequencies of usRNA ormsRNA producing cells observed
after TCR or HDACi stimulation may be due, at least in part, to cell death
after stimulation, reductions in cell viability following TCR stimulation
wasminimal, and b17% in the setting of RMD exposure. Despite themin-
imal reductions in cell viability, our results may have been influenced by
differential loss of HIV-infected cells following viral reactivation.
We included individuals with various clinical settings, including
those on long-term ART who initiated treatment during chronic infec-
tion and two participants that had no detectable HIV reservoirs follow-
ing allogeneic HSCT, but experienced viral rebound following ART
cessation that mimicked acute infection (Henrich et al., 2014, 2013).
These patients were included as to test the scdPCR assay in the diverse
populations that may be incorporated into HIV eradication studies. As
above, participant A experienced a decrease in HIV-1 usRNA following
ex vivo romidepsin exposure, and was only on 3 months of ART prior
to sampling. Given similar cell viabilities with or without stimulation,
factors other than cell death likely led to this interesting observation.
Results from a single individual are clearly not sufficient to make any
conclusions regarding the responses to HDAC inhibitor exposure, but
it possible that the observed differences in response to stimulation be-
tween participants may be due to factors such as the burden of HIV-1-
infection in various T cell immune subsets, CD4+ T cell activation and
proliferation state or exhaustion phenotype at the time of sampling
(Chomont et al., 2009). It is also possible that technical differences be-
tween the traditional and single-cell-in droplet PCR methods led to
these varied and sometimes, dichotomous observations. Further inves-
tigation in larger, controlled cohorts is needed, and comparisons of
scdPCR with recently described single-cell quantification methods in-
volving intracellular HIV-1 RNA in-situ hybridization or HIV antigen de-
tection (Baxter et al., 2016) are warranted.The scdPCR method carries several limitations. For example, despite
its ability to encapsulate single cells, cells may be lost during packaging
and subsequent droplet manipulation (e.g., sample transfer prior to
thermocycling). In addition, a small percentage of droplets contain
greater than a single cell as detailed above which may bias subsequent
downstream characterization of individual cells. Nonetheless, we ob-
served a high degree of reproducibility between independent experi-
ments, and levels measured in our patient population were within the
linear range of the assay. The assay is also limited by the lack of capacity
to provide a direct measure of the percentage of individual cells to pro-
duce replication competent virus, such as with the quantitative viral
outgrowth assay (qVOA) (Chun et al., 1997; Eriksson et al., 2013; Ho
et al., 2013; Laird et al., 2013; Siliciano and Siliciano, 2005). A large pro-
portion of intracellular HIV-1 DNA and RNA do not code for replication
competent virus (Ho et al., 2013), and our assay is not designed to enu-
merate individual cells that may harbor the true replication competent
reservoir. Nonetheless, it is of utmost importance to determine the
changes in HIV transcriptional activity of infected cells in response to
various stimuli. Cells were rested overnight prior to stimulation,
which may also have led to increases in HIV transcriptional activity
without exogenous stimuli. However, the assay allows the capacity for
cells to be encapsulated rapidly following thawing. We were also able
to identify transcriptionally active cells from patients without exoge-
nous stimulation, thereby allowing application of scdPCR to samples ob-
tained from in vivo LRA administration.
In thismanuscript, we have performed proof-of-concept studies that
demonstrate transcriptionally active, HIV-1- infected and transcription-
ally active cellsmay be isolated, allowing for downstreamquantification
of genomic DNA ormRNA. Integrating the scdPCR assaywith previously
described fluorescent activated droplet sorting(Baret et al., 2009) may
provide a platform in which infected, reactivated HIV-1+ cells can be
sorted, isolated, and characterized in a larger number of samples. Our
assay may also provide several advantages over previously published
or commercialized single-cell platforms. For example, the Fluidigm sys-
tem allows for deep transcriptional characterization of single cells, but is
limited by the relatively low input cells (e.g. 96 to 384) and relatively
high cost of processing a single cell. Other platforms such as 10X Geno-
mics microfluidic encapsulation platform and the published DropSeq
protocol allow for input of larger number of cells (e.g. thousands), but
may lack the throughput to cost-effectively screen the millions of cells
required to characterize HIV-1 infection in ART-suppressed individuals
(Macosko et al., 2015; Shalek et al., 2014; Trivedi et al., 2015; Zheng et
al., 2017). These platforms were also originally designed for the detec-
tion of polyadenylated mRNA rather than for specific viral targets, as
in scdPCR.
In summary, the quantification of the number of directly observed,
individual cells expressing RNA, has the potential to provide insight
into how individuals will respond to various HIV reactivation strategies.
Our results demonstrate that there may be important inter-patient dif-
ferences between the number of transcriptionally reactivated cells and
the total amount of HIV RNA produced. As a result, our methods may
play an important role in determining whether potential increases in
cell-associated HIV-1 RNA following reservoir reactivation result from
a small number of highly active cells or from a larger, less active pool.Conflicts of Interest
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